g(m1)-ganglioside has been researched along with Necrosis* in 3 studies
3 other study(ies) available for g(m1)-ganglioside and Necrosis
Article | Year |
---|---|
Effects of ganglioside G(M1) and erythropoietin on spinal cord lesions in rats: functional and histological evaluations.
To evaluate the functional and histological effects of ganglioside G(M1) and erythropoietin after experimental spinal cord contusion injury.. Fifty male Wistar rats underwent experimental spinal cord lesioning using an NYU-Impactor device and were randomly divided into the following groups, which received treatment intraperitoneally. The G(M1) group received ganglioside G(M1) (30 mg/kg); the erythropoietin group received erythropoietin (1000 IU/kg); the combined group received both drugs; and the saline group received saline (0.9%) as a control. A fifth group was the laminectomy group, in which the animals were subjected to laminectomy alone, without spinal lesioning or treatment. The animals were evaluated according to the Basso, Beattie and Bresnahan (BBB) scale, motor evoked potential recordings and, after euthanasia, histological analysis of spinal cord tissue.. The erythropoietin group had higher BBB scores than the G(M1) group. The combined group had the highest BBB scores, and the saline group had the lowest BBB scores. No significant difference in latency was observed between the three groups that underwent spinal cord lesioning and intervention. However, the combined group showed a significantly higher signal amplitude than the other treatment groups or the saline group (p<0.01). Histological tissue analysis showed no significant difference between the groups. Axonal index was significantly enhanced in the combined group than any other intervention (p<0.01).. G(M1) and erythropoietin exert therapeutic effects on axonal regeneration and electrophysiological and motor functions in rats subjected to experimental spinal cord lesioning and administering these two substances in combination potentiates their effects. Topics: Animals; Drug Therapy, Combination; Erythropoietin; G(M1) Ganglioside; Injections, Intraperitoneal; Locomotion; Male; Models, Animal; Necrosis; Neuroprotective Agents; Random Allocation; Rats, Wistar; Reaction Time; Recovery of Function; Spinal Cord Injuries | 2016 |
Attenuation of cortical neuronal apoptosis by gangliosides.
Addition of the natural gangliosides monosialoganglioside (GM1), disialoganglioside, trisialoganglioside, or tetrasialoganglioside in the range of 10 to 100 microM, but not asialoganglioside lacking the sialic acid moiety, attenuated cortical neuronal apoptosis induced by serum deprivation, ionomycin, or cyclosporin A but not by protein kinase inhibitors (staurosporine, genistein, lavendustin A, or herbimycin A). Coaddition of 100 nM wortmannin, a selective inhibitor of phosphatidylinositol 3-kinase, but not 1 microM Go6976, a selective protein kinase C inhibitor, blocked the neuroprotective effect of GM1. In contrast to its antiapoptotic effect, GM1 at up to 200 microM did not attenuate cortical neuronal necrosis induced by exposure to the excitotoxins N-methyl-D-aspartate or kainate. Furthermore, GM1 increased the necrosis induced by oxidative stress (addition of Fe(2+) or buthionine sulfoximine). These data suggest that neuroprotective effects of natural gangliosides may preferentially reflect reduction of neuronal apoptosis rather than necrosis, and be mediated through mechanisms involving activation of phosphatidylinositol 3-kinase. Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; Culture Media, Serum-Free; Cyclosporine; Enzyme Inhibitors; Excitatory Amino Acid Agonists; G(M1) Ganglioside; Gangliosides; Ionomycin; Mice; N-Methylaspartate; Necrosis; Neurons; Oxidative Stress; Phosphorylation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 1999 |
The role of the monosialoganglioside, GM1 as a neuroprotectant in an experimental model of cardiopulmonary bypass and hypothermic circulatory arrest.
Twelve male dogs were placed on closed-chest cardiopulmonary bypass, subjected to 2 h of HCA at 18 degrees C, and rewarmed to 37 degrees C on closed-chest cardiopulmonary bypass. All animals were mechanically ventilated and monitored for 20 h before extubation and survived for 3 days. Group 1 dogs (n = 6) were pretreated with GM1, 30 mg/kg/24 h for 3 days before HCA, and received continuous infusion of GM1 during the procedure and 30 mg/kg/24 h for 3 days after HCA. Group 2 dogs (n = 6) received vehicle only. With a species-specific behavior scale that yielded a neurodeficit score ranging from 0% (normal) to 100% (brain dead), all animals were neurologically assessed every 12 h by two observers. After death at 72 h, brains were examined by glutamate receptor autoradiography and by histologic examination for patterns of selective neuronal necrosis and were scored blindly from 0 (normal) to 100 (severe injury). These results provide evidence of a role for GE in the development of HCA-induced brain injury and suggest that monosialogangliosides may have a neuroprotective effect in prolonged periods of HCA. Topics: Animals; Autoradiography; Brain; Brain Death; Cardiopulmonary Bypass; Dogs; G(M1) Ganglioside; Heart Arrest, Induced; Hypothermia, Induced; Infusions, Intravenous; Male; Necrosis; Neurons; Neuroprotective Agents; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Reperfusion | 1998 |